TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
TG Therapeutics has announced data presentations at the American Academy of Neurology 2026 Annual Meeting highlighting the clinical and real-world effectiveness, safety, and optimized dosing of BRIUMVI (ublituximab-xiiy) for relapsing multiple sclerosis (RMS). These data include findings from the Phase 4 ENABLE observational study and the ENHANCE d…